Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga

Stock Market Rises In Range; Palantir, AMD, Shopify Lead Huge Earnings Movers: Weekly Review

The stock market indexes had big weekly gains despite some daily swings. Palantir and Shopify were among huge earnings movers.

Investors Business Daily

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Investors Business Daily

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Barchart

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Dow Leads as Merck, Amgen Gain: Stock Market Today

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Barchart

Amgen: How To Find And Own America's Greatest Opportunities

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.

Investors Business Daily

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Investors Business Daily

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

AAP

Microsoft Copilot is "pretty important" but customers still prefer ChatGPT — "OpenAI has done a tremendous job"

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

Windows Central

New once-a-month drug could treat diabetes and obesity, scientists say

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

The Independent UK

Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent

Amgen presented promising results for its weight-loss drug. But not everyone is convinced.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Investors Business Daily

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Kiplinger

Stock Market Today: Nasdaq Outperforms as Big Tech Rallies

The Dow Jones Industrial Average closed lower for a second day as Amgen and Merck fell.

Investors Business Daily

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

12 Stocks Blow Away Warren Buffett's Long-Term Track Record

Warren Buffett's Berkshire Hathaway sports an enviable long-term track record. But not even Buffett is No. 1 in the S&P 500 in the long run.

Barchart

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

Investors Business Daily

Dow Jones Rallies On Surprise Jobs Report; Apple Dives On Earnings

The Dow Jones rallied Friday on a surprise April jobs report. Apple stock dived on earnings on the stock market today.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

Barchart

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Fortune

Elon Musk’s retreat from DOGE has lifted Tesla’s valuation by $158 billion—but the stock is still 50% off its peak

A TSLA stock rebound led to gains surpassing the current market caps of Amgen or Adobe.

Barchart

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations